← Back to all trials
Not Yet Recruiting
NCT05670821
PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms
Conditions: Generalized Pustular Psoriasis
Sex: All
Ages: 18 Years – N/A
Enrollment: 38
Sponsor: Boehringer Ingelheim
Summary
Non-interventional cohort study in patients with newly initiated Spesolimab to evaluate the incidence of adverse drug reactions and to understand generalized pustular psoriasis (GPP) disease activities in the real world setting.
Eligibility Criteria
Inclusion Criteria:GPP patients with acute symptoms who are administered Spesolimab Intravenous (I.V.) Infusion in JapanPatients who have never been treated with Spesolimab I.V. Infusion before enrolmentExclusion Criteria:None
Source: ClinicalTrials.gov (NCT05670821). StuddyBuddy aggregates publicly available trial information.
